Record Date for Dividend - Correction

RNS Number : 2902N

Medica Group PLC

29 September 2021

 

29 September 2021

Medica Group PLC

Record Date for Dividend - Correction

The following amendment has been made to the 'Interim results for the six months to 30 June 2021' announcement released on 27 September 2021 at 07:00 under RNS No: 9760M.

The record date stated under the Dividend section is corrected from 07 October 2021 to 08 October 2021.

All other details remain unchanged.

The full amended text is as follows:

Dividend

For the period to 30 June 2021, the board has decided to declare an interim dividend of 0.89p per share which will be paid on 05 November 2021 to shareholders on the register as at 08 October 2021 (ex-dividend date 07 October 2021). This represents an increase of 4.7% over the prior year interim dividend of 0.85 pence per share.

The Board has considered the performance of the business and the cash requirements to support the growth strategy and will continue to review our dividend policy in line with our intention that it remains progressive.

For further information, please contact:

Medica Group Dr. Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer	[phone]
Investec Bank plc Sara Hale Daniel Adams	[phone]
Liberum Bidhi Bhoma Richard Lindley Euan Brown	[phone]
FTI Consulting Sam Purewal Victoria Foster Mitchell	[phone]

About Medica Group PLC

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland. In the US Medica via its subsidiary RadMD, provides highly specialised services to support the use of imaging in a clinical trial setting.

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition,  Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.

The Company currently offers two primary services to hospital radiology departments:

·   NightHawk - urgent reporting service

·   Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.

Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.

For more information please visit:  www.medicagroupplc.com  

 

END

 

 

MSCSEAFWAEFSEEU